INDOLENT LYMPHOMA
Clinical trials for INDOLENT LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new INDOLENT LYMPHOMA trials appear
Sign up with your email to follow new studies for INDOLENT LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for Hard-to-Treat lymphoma patients
Disease control Not yet recruitingThis study tests a daily oral drug called lisaftoclax in 75 adults with slow-growing lymphomas (CLL, WM, or MZL) who cannot take or have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control the cancer. Treatment continues as …
Matched conditions: INDOLENT LYMPHOMA
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 17, 2026 06:43 UTC
-
New combo aims to tame returning lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have returned or not responded to prior treatment. The first part finds the safest dose, and the second part checks how well the combo…
Matched conditions: INDOLENT LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 04, 2026 16:19 UTC